Jean-Paul Castaigne
Director/Board Member presso Tranzyme Pharma, Inc. (Canada)
Profilo
Jean-Paul Castaigne currently works at BioQuebec, as Director and Tranzyme Pharma, Inc. (Canada), as Director.
Dr. Castaigne also formerly worked at Angiochem, Inc., as President & Chief Executive Officer, JPC Consulting, as Chief Executive Officer, Trillium Therapeutics ULC, as Director from 2006 to 2007, Ocera Therapeutics, Inc., as Independent Director from 2011 to 2015, Asmacure Ltée, as Director, Novartis Groupe France SA, as Director-Medical, Research & Development, Allostera Pharma, Inc., as Director from 2006 to 2013, Novartis Healthcare Philippines, Inc., as President & Managing Director, Fondation Sur Les Leucodystrophies, as Director, ConjuChem, Inc., as Chief Operating & Scientific Officer, Cilag AG, as Principal, Novartis Pharmaceuticals Canada, Inc., as Vice President, Saint Jean Industries Lorraine SAS, as Vice President, Head-Global Research & Development, and Sanofi-Aventis Canada, Inc., as Principal.
Dr. Castaigne received his doctorate degree in 1975 from Université Paris 1 Panthéon-Sorbonne and Masters Business Admin degree in 1987 from École des Hautes Études Commerciales de Paris.
Posizioni attive di Jean-Paul Castaigne
| Società | Posizione | Inizio |
|---|---|---|
| Tranzyme Pharma, Inc. (Canada) | Director/Board Member | - |
BioQuebec
 BioQuebec BiotechnologyHealth Technology BioQuebec is the largest biotechnology and life sciences network in Quebec, Canada. The private company is based in Bromont, Canada. BioQuebec's 130 members include companies and organizations that operate at every level of the biotechnology and life sciences innovation chain, ranging from biotechs to pharmas, contract research organizations, venture capital firms, and support organizations. The Canadian company engages in governmental representation, business development, and partnerships to support the growth of Quebec's biotechnology and life sciences industry, which creates wealth and specialized jobs, is focused on innovation and marketing, and is dedicated to improving everyone's health and quality of life. BioQuebec's actions aim to make Quebec one of the industry's most significant and valuable players on the international stage. The company was founded in 1991 by Pierre Alary, and the CEO is Mario Lebrun. | Director/Board Member | - |
Precedenti posizioni note di Jean-Paul Castaigne
| Società | Posizione | Fine |
|---|---|---|
| OCERA THERAPEUTICS INC | Director/Board Member | 18/06/2015 |
Allostera Pharma, Inc.
 Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | Director/Board Member | 09/09/2013 |
| TRILLIUM THERAPEUTICS | Director/Board Member | 15/10/2007 |
Fondation Sur Les Leucodystrophies
 Fondation Sur Les Leucodystrophies Miscellaneous Commercial ServicesCommercial Services Fondation Sur Les Leucodystrophies supports research in identifying the causes of leuko dystrophies. The company was founded by Marjolaine Verville and Eric Tailleur and is headquartered in Québec, Canada. | Director/Board Member | - |
Sanofi-Aventis Canada, Inc.
 Sanofi-Aventis Canada, Inc. Pharmaceuticals: MajorHealth Technology Sanofi-aventis Canada Inc. is the Canadian affiliate of the sanofi-aventis Group, one of the world's leading pharmaceutical companies. They are headquartered in Laval, Quebec, and employ 900 people across the country. Their Laval site is also home to a world-class manufacturing facility that produces medications for use by patients in Canada, the United States and other countries. As a leading healthcare partner they provide, and are developing, innovative medicines for treatments in several therapeutic areas: cardiovascular disease, thrombosis, oncology, metabolic disorders, the central nervous system, and internal medicine. They also play a role by investing in activities that improve health and quality of life in their communities. The sanofi-aventis Group is also represented in Canada by Sanofi Pasteur Limited. Located in Toronto, the company is Canada's largest producer of vaccines and employs 1,200 people. | Corporate Officer/Principal | - |
Formazione di Jean-Paul Castaigne
| Université Paris 1 Panthéon-Sorbonne | Doctorate Degree |
| École des Hautes Études Commerciales de Paris | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 16 |
|---|---|
ConjuChem, Inc.
 ConjuChem, Inc. Pharmaceuticals: MajorHealth Technology ConjuChem, Inc. is a biotechnology company that has developed the Drug Affinity Complex (DAC™) Technology, a platform enabling the rapid creation of improved, patentable drugs from existing small organic compounds or peptides. | Health Technology |
Trillium Therapeutics ULC
 Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
Ocera Therapeutics, Inc.
 Ocera Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ocera Therapeutics, Inc. manufactures pharmaceuticals products. The company was founded in 2004 and is headquartered in Hazelwood, MO. | Health Technology |
Angiochem, Inc.
 Angiochem, Inc. Pharmaceuticals: MajorHealth Technology Angiochem, Inc. is a clinical-stage biotechnology company, which engages in the development of pharmaceutical drugs for brain diseases and brain-related disorders. It offers small molecules and biologics, for the treatment of central nervous system diseases including primary brain cancer, brain metastases, lysosomal storage diseases, and pain. The company founded by Richard Béliveau in 2003 and is headquartered in Montreal, Canada. | Health Technology |
Asmacure Ltée
 Asmacure Ltée Pharmaceuticals: MajorHealth Technology Asmacure Ltée develops novel, proprietary compounds that target cholinergic receptors for the treatment of inflammation, notably pulmonary airway diseases. The company was founded by Yvon Cormier and Evelyne Israel-Assayag in 2002 and is headquartered in Quebec, Canada. | Health Technology |
Cilag AG
 Cilag AG Miscellaneous Commercial ServicesCommercial Services Cilag AG conducts pharmaceutical research and development activities. It is an international operating company integrated in the pharmaceuticals group of Johnson & Johnson that provides its customers with APIs, health care and pharmaceutical products worldwide. The company was founded in 1936 by Dr. Bernhard Joos and is headquartered in Schaffhausen, Switzerland. | Commercial Services |
Novartis Groupe France SA
 Novartis Groupe France SA Financial ConglomeratesFinance Novartis Groupe France SA is a pharmaceutical company. It provides cure for diseases. The company is headquartered in Rueil-Malmaison, France. | Finance |
BioQuebec
BioQuebec BiotechnologyHealth Technology BioQuebec is the largest biotechnology and life sciences network in Quebec, Canada. The private company is based in Bromont, Canada. BioQuebec's 130 members include companies and organizations that operate at every level of the biotechnology and life sciences innovation chain, ranging from biotechs to pharmas, contract research organizations, venture capital firms, and support organizations. The Canadian company engages in governmental representation, business development, and partnerships to support the growth of Quebec's biotechnology and life sciences industry, which creates wealth and specialized jobs, is focused on innovation and marketing, and is dedicated to improving everyone's health and quality of life. BioQuebec's actions aim to make Quebec one of the industry's most significant and valuable players on the international stage. The company was founded in 1991 by Pierre Alary, and the CEO is Mario Lebrun. | Health Technology |
Novartis Pharmaceuticals Canada, Inc.
 Novartis Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Canada, Inc. manufactures chemicals and pharmaceuticals products. It provides solutions on patients suffering from a variety of major illnesses including cancer, cardiovascular diseases, Alzheimer's disease, age-related macular degeneration, organ transplantation, and osteoporosis. The company was founded in 1996 and is headquartered in Dorval, Canada. | Health Technology |
JPC Consulting
 JPC Consulting Information Technology ServicesTechnology Services JPC Consulting provides IT solution. The company is headquartered in Hicksville, NY. | Technology Services |
Allostera Pharma, Inc.
Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | Distribution Services |
Saint Jean Industries Lorraine SAS
 Saint Jean Industries Lorraine SAS Metal FabricationProducer Manufacturing Saint Jean Industries Lorraine SAS specializes in the design and the production of prototype parts. The firm offers molded housings for the automotive, hydraulic components and agro alimentary industries. The company was founded in 1983 and is headquartered in Harol, France. | Producer Manufacturing |
| Tranzyme Pharma, Inc. (Canada) | |
| Novartis Healthcare Philippines, Inc. | |
Sanofi-Aventis Canada, Inc.
Sanofi-Aventis Canada, Inc. Pharmaceuticals: MajorHealth Technology Sanofi-aventis Canada Inc. is the Canadian affiliate of the sanofi-aventis Group, one of the world's leading pharmaceutical companies. They are headquartered in Laval, Quebec, and employ 900 people across the country. Their Laval site is also home to a world-class manufacturing facility that produces medications for use by patients in Canada, the United States and other countries. As a leading healthcare partner they provide, and are developing, innovative medicines for treatments in several therapeutic areas: cardiovascular disease, thrombosis, oncology, metabolic disorders, the central nervous system, and internal medicine. They also play a role by investing in activities that improve health and quality of life in their communities. The sanofi-aventis Group is also represented in Canada by Sanofi Pasteur Limited. Located in Toronto, the company is Canada's largest producer of vaccines and employs 1,200 people. | Health Technology |
Fondation Sur Les Leucodystrophies
Fondation Sur Les Leucodystrophies Miscellaneous Commercial ServicesCommercial Services Fondation Sur Les Leucodystrophies supports research in identifying the causes of leuko dystrophies. The company was founded by Marjolaine Verville and Eric Tailleur and is headquartered in Québec, Canada. | Commercial Services |
- Borsa valori
- Insiders
- Jean-Paul Castaigne
